Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CDK inhibitor R547

Known as: CDKI R547, Cyclin Dependent Kinase Inhibitor R547, Cyclin-Dependent Kinase Inhibitor R547 
An orally bioavailable diaminopyrimidine compound and a cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. CDKs are ATP… Expand
National Institutes of Health

Related topics

Related topics

5 relations
Cyclin-Dependent KinasesNCIt Antineoplastic Agent TerminologyNegative Regulation of G1 PhaseNegative Regulation of G2 to M Transition
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Marine Protists Are Not Just Big Bacteria
The study of marine microbial ecology has been completely transformed by molecular and genomic data: after centuries of relative… Expand
  • figure 1
  • figure 2
  • figure 3
Review
2014
Review
2014
Signaling pathways in breast cancer: therapeutic targeting of the microenvironment.
Breast cancer is the most common cancer in women worldwide. Understanding the biology of this malignant disease is a prerequisite… Expand
  • figure 1
  • figure 2
2013
2013
The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy
Abstract We prepared and evaluated transferrin (Tf) and monoclonal antibody (mAb) 2C5-modified dual ligand-targeted poly(ethylene… Expand
Highly Cited
2011
Highly Cited
2011
Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks
BackgroundHigh-throughput measurement technologies produce data sets that have the potential to elucidate the biological impact… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2009
2009
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients
A genomics-based approach to identify pharmacodynamic biomarkers was used for a cyclin-dependent kinase inhibitory drug. R547 is… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2007
2007
A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs)
3528 Background: R547, a potent inhibitor of CDKs 1, 2, 4, 7, and 9, has shown broad antitumor activity in preclinical models… Expand
Highly Cited
2006
Highly Cited
2006
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
The cyclin-dependent protein kinases are key regulators of cell cycle progression. Aberrant expression or altered activity of… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Highly Cited
2006
Highly Cited
2006
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant…
The cyclin-dependent kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. Since deregulation of CDKs is… Expand
2004
2004
Expression and Activity of the CDK Inhibitor p57Kip2 in Chondrocytes Undergoing Hypertrophic Differentiation
Growth plates ofp57‐null mice exhibit several abnormalities, including loss of collagen type X (CollX) expression. The phenotypic… Expand
Highly Cited
2003
Highly Cited
2003
Thyroid hormone regulates the cell cycle inhibitor p27Kip1 in postnatal murine Sertoli cells.
Thyroid hormone regulates early postnatal Sertoli cell proliferation. Transient neonatal hypothyroidism allows prolonged… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE